Hair Loss Causes and the Treatments That Work
What causes hair loss and how does the cause determine which treatment works?
Two people can use the identical product for a year and get opposite results, and the reason almost never has anything to do with the product. Hair loss isn't one condition, it's a handful of very different ones that happen to look similar in the mirror, and the treatment that holds ground against one of them does nothing at all against another. Where you land in that split decides everything you spend from that point on.
Androgenetic alopecia accounts for most long term loss in men and a large share in women and progresses through DHT driven miniaturization that returns to its untreated course within about twelve months of stopping therapy, while telogen effluvium, autoimmune, deficiency related, and scarring causes each require a different approach and only scarring alopecia destroys the follicle permanently.
Which types of hair loss are most common and how are they distinguished?
Most of this is settled by reading the map on your scalp, before anyone runs a single test. The shape of the loss, where it sits, and how fast it arrived tell you more than a blood panel will. Mixed presentations are common enough that you should expect them rather than treat them as unusual.
- Androgenetic alopecia: Patterned and bilateral, temples and crown in men, widening central part in women, ear to ear band untouched.
- Telogen effluvium: Diffuse across the whole scalp, heavy shedding rather than a bald area, trigger two to three months earlier.
- Alopecia areata: Sharply defined round or oval patches of smooth skin, sometimes with short tapered hairs at the border.
- Traction alopecia: Thinning at the temples and frontal rim from tight braids, extensions, or pulled back styles.
- Scarring alopecia: Shiny smooth surface with no follicular openings, often with redness or scaling at the edge.
The loss of visible follicular openings is what separates scarring alopecia from every non scarring type, and a pull test that releases more than roughly three hairs from a grasped bundle of sixty points to active shedding rather than the slow miniaturization of pattern loss.
How does androgenetic alopecia damage follicles over time?
Nothing about this is sudden. It's a slow accounting problem, where each growth cycle returns a slightly smaller hair than the one before it, and the shortfall compounds until there's nothing left to shrink.
- Shortened anagen: A healthy follicle grows for two to six years. Under androgen pressure that drops to two years, then one, then months.
- Bulb shrinkage: The follicular bulb shrinks in parallel, so each replacement hair emerges thinner in diameter and less pigmented.
- Mixed calibers: Different thicknesses sit side by side on the scalp, which is the most reliable early sign, since a normal scalp shows uniform thickness.
- Rising telogen fraction: More follicles sit resting and empty at any moment, so density loss compounds on top of the caliber loss.
- Involution: The follicle crosses from vellus to a structure replaced by fibrous streamers in the dermis, and that crossing is permanent.
A miniaturized but living follicle can be pushed back toward terminal caliber by therapy that lengthens the anagen phase or blocks the hormonal signal, but a follicle that has completed involution can't be recovered by any drug, and trichoscopy detects shaft diameter diversity above roughly twenty percent in men and ten percent in women well before the change is visible in a mirror.
What role do hormones like DHT play in pattern hair loss?
Here's the part that surprises most men: your testosterone is almost certainly normal. The problem isn't how much hormone you have, it's how sensitive certain follicles are to a perfectly ordinary amount of it, and that sensitivity was set during development.
- The conversion: 5 alpha reductase, with type 2 concentrated in the follicle, turns circulating testosterone into DHT.
- The binding: DHT binds the androgen receptor with roughly five times the affinity of testosterone, triggering changes in the dermal papilla.
- The regional map: Front and crown follicles carry higher receptor and enzyme levels than the occipital band, which is why loss follows a predictable shape.
- The tradeoff: Systemic androgen suppression carries an uncommon but documented profile including reduced libido, erectile difficulty, and mood changes.
Blood testosterone results are almost always normal in men with pattern loss because the condition comes from follicle sensitivity rather than hormone excess, while in women signs of androgen excess such as irregular cycles, acne, or unwanted facial hair should prompt measurement of free testosterone, DHEAS, and related markers.
When is hair shedding temporary rather than permanent?
The tell is timing, not volume. Follicles pushed out of growth don't release their hairs immediately, they sit resting for two to three months and then let go together, which is exactly why you probably can't connect the shedding to the event that caused it without being prompted.
Shedding fifty to one hundred hairs a day is normal, and a telogen effluvium that follows a single resolved trigger typically returns to full density over six to twelve months, while shedding that persists beyond six months signals an unresolved cause and warrants reassessment rather than continued waiting.
How do nutritional deficiencies and medical conditions trigger hair loss?
Follicles divide faster than almost any other cell population in your body, which makes them expensive to run and one of the first systems the body throttles back when supply or regulation falters. That's a useful way to think about this whole category: your hair isn't sick, it's been deprioritized.
- Iron: Ferritin can sit inside the lab reference range and still be too low for hair, so many clinicians look for roughly forty to seventy nanograms per milliliter.
- Thyroid: Thyroid hormone regulates follicular cycle timing, and both hypothyroidism and hyperthyroidism produce diffuse thinning.
- Protein and calorie restriction: Very low calorie dieting and bariatric surgery cut the amino acid supply the shaft is built from.
- Medication: Retinoids, some antidepressants and anticonvulsants, beta blockers, anticoagulants, and high dose vitamin A are all recognized contributors.
- Autoimmune activity: The immune system attacks the bulb directly in alopecia areata, while lupus and lichen planopilaris can destroy the follicular unit permanently.
Correcting a deficiency stops the ongoing insult and restores hair that was shed but does not reverse genetic miniaturization running underneath, and excess vitamin A or selenium can itself cause the very shedding the supplement was bought to fix.
Which diagnostic tests confirm the cause before treatment begins?
A good assessment runs cheapest to most invasive and stops the moment the answer is clear. You're not buying a battery of tests, you're buying an answer, and most of the time it arrives long before anyone reaches for a needle.
- History: Timeline, family pattern, recent illness, medication list, and styling habits settle a large share of cases before anyone touches your scalp.
- Examination: Patterned versus diffuse, preserved versus lost follicular openings, and any inflammation, scaling, or the smooth shine of scarring.
- Trichoscopy: Dermoscopy of the scalp at twenty to seventy times magnification, the highest yield instrument in routine use and nearly free to perform.
- Pull test: More than roughly three hairs released from a bundle of sixty supports effluvium, and a negative test with obvious thinning supports pattern loss.
- Targeted blood work: Complete blood count, ferritin, thyroid stimulating hormone, and vitamin D, with hormone markers added where androgen excess is suspected.
- Scalp biopsy: Reserved for what the clinic can't settle otherwise, above all confirming or excluding a scarring alopecia.
Standardized global photography under fixed lighting and framing, repeated at three and six months, is what converts subjective impressions into evidence, because both patients and clinicians judge density change poorly from memory.
Why do the same treatments fail on scarring alopecia?
Every treatment that works in pattern loss quietly assumes there's a living follicle to act on. In scarring alopecia that assumption is simply false, which is how someone applies the standard therapies faithfully for a year in a scarred zone and sees literally nothing.
| Criteria | Pattern loss | Scarring alopecia |
|---|---|---|
| Follicle status | Miniaturized but alive | Stem cells destroyed, unit replaced by fibrous tissue |
| Target of treatment | Growth phase and hormonal pathway | Inflammation around the bulge region |
| Realistic goal | Stabilize and partially thicken | Halt the disease, no regrowth from scarred sites |
| Warning signs | Gradual thinning, mixed calibers | Itching, burning, tenderness, redness, scaling, smooth shiny patch |
| Surgical option | Standard once density warrants it | Only after documented quiescence, typically one to two years |
Once the stem cells around the bulge region are destroyed the follicular unit is replaced by fibrous connective tissue and no growth stimulant or hormonal blocker has anything left to act on, so a smooth shiny patch where the pinpoint follicular openings have disappeared warrants prompt evaluation rather than another month of waiting.
How does the stage of miniaturization affect what a treatment can recover?
Stage sets the ceiling and no treatment negotiates with it. Here's the uncomfortable arithmetic: your scalp can lose a substantial share of its density before thinning is obvious in ordinary lighting, so by the time you go looking for help, a substantial share of the work is already done.
Transplanted hair is permanent but the native hair around it isn't, so grafts placed without addressing ongoing miniaturization can leave an isolated island of transplanted hair within about five years as surrounding native density falls away, which is why medical therapy is normally maintained alongside and after surgery rather than replaced by it.
What happens when the wrong treatment is chosen for the underlying cause?
The damage from a misdirected plan is rarely the money. It's the calendar. Pattern loss advances whether or not you're applying something to it, so a year aimed at the wrong mechanism is a year in which salvageable follicles finish involuting, and those don't come back when the correct treatment finally starts.
- Lost surgical options: That year can be the difference between a plan with sufficient donor supply and one where demand outstrips what can be harvested.
- Actively harmful choices: A scarring alopecia treated as pattern loss loses the narrow window for suppressing inflammation, and aggressive mechanical or chemical scalp treatments add irritation on top.
- The perception trap: Products look like they work for two to four months because conditioning and styling make hair appear fuller, and a resolving effluvium regrows on its own schedule regardless.
- The behavioral cost: People who've already invested in something that failed become harder to persuade to commit to the treatment that would have worked.
No meaningful change on objective measures at the six month mark should trigger a return to the diagnosis rather than an escalation of the same approach, checking whether adherence was genuine, whether a second cause such as low ferritin or thyroid disease is running underneath, and whether the original classification was correct.
How do treatment options differ between men and women?
Most people assume the difference is cosmetic, a matter of where the thinning shows. It isn't. The differential is broader in women, the pharmacology is genuinely restricted, and the goals people bring to the conversation are usually different too.
| Criteria | Men | Women |
|---|---|---|
| Presentation | Receding temples, crown thinning | Widening central part, hairline largely spared |
| Diagnostic workup | Narrow, hormone panels rarely useful | Broad, includes iron, thyroid, PCOS, postpartum, traction |
| Androgen blocking agents | Standard option | Teratogenic, contraindicated in pregnancy and breastfeeding |
| Typical first line for younger patients | Systemic and topical pathway therapy | Topical growth stimulants, deficiency correction, procedural options |
| Surgical candidacy | Donor band usually stable | Stricter selection, diffuse occipital thinning reduces graft quality |
Androgen blocking agents are teratogenic and contraindicated in women who are pregnant, may become pregnant, or are breastfeeding, so prescribing in premenopausal women requires reliable contraception and an explicit discussion, while systemic anti androgen approaches become more straightforward after menopause.
